



Educational Research (ISSN: 2141-5161) Vol. 12 (4)

Available online @ <http://www.interestjournals.org/ER>

Copyright © 2021 International Research Journals

Short Communication

Translation of Evidence into Nursing Leadership & Management

Abdulqadir J. Nashwan

Hamad Medical Corporation, Doha 3050, Qata University of Calgary in Qatar, Doha, Qata

Abstract

In the past, nurses used to provide clinical care, even though no substantial evidence supported this practice following basic logical assumptions. Usually, health care providers (HCPs) including nurses often follow outdated policies and procedures without questioning their current practices in terms of accuracy, safety, feasibility, and applicability. This presentation aims to provide an overview of the applications of translating evidence on leadership and management. Nurses are collaborating with other healthcare providers to develop new and innovative ways to translate evidence into practice to provide the best quality of care while maintaining the highest levels of safety standards. Nursing leaders need to build the infrastructure (policies, processes, resources, etc.) for transfer of knowledge into practice through empowering environment for nurses. Nursing leaders/managers face increasing demands to provide expertise in implementing evidence-based nursing care to meet the healthcare needs of diverse patient populations.

Biography

Abdulqadir Nashwan is a Director of Nursing for Education and Practice Development at HMGH a member of Hamad Medical Corporation (HMC) in Qatar. As well as a Senior Adjunct Instructor at the faculty of nursing at the University of Calgary in Qatar (UCQ). His current research interests include Research Utilization, Evidenced-Based Practice, Hematology/Oncology, Nursing Informatics, and Cancer Immunotherapy. Mr. Nashwan has published more than 50 research articles in reputable peer-reviewed journals. In November 2015, he received the Award of Merit for Placing HMC at the Cutting Edge of Cancer Research as a part of Stars of Excellence Program introduced by HMC. In October 2016, Mr. Nashwan completed a Cancer Biology & Therapeutics (CBT) Program; provided by Harvard Medical School (HMS).

Reference:

1. Pippard M. Iron chelation therapy in the treatment of iron overload. In: Bergeron R, Brittenham G, editors. *The Development of Iron Chelators for Clinical Use*. Boca Raton, FL: CRC Press; 1994. pp. 57–74.
2. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. *Nat Med*. 2007;13:1096–1101. doi: 10.1038/nm1629.
3. Andrews NC. Disorders of iron metabolism. *N Engl J Med*. 1999;341:1986–1995. doi: 10.1056/NEJM199912233412607
4. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. *Blood*. 2006;107:3436–3441. doi: 10.1182/blood-2006-02-002394

Cite this article: Abdulqadir J. Nashwan, Translation of Evidence into Nursing Leadership & Management
Euro Nursing 2021; October 22-23, 2021; Paris, France